华神科技(000790) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 was ¥205,237,923.08, an increase of 8.36% compared to the same period last year[2]. - The net profit attributable to shareholders was -¥3,371,133.67, a decrease of 153.52% year-on-year[2]. - The pharmaceutical business achieved revenue of ¥44,614,540, a year-on-year increase of 61.13%, while the construction steel structure business saw a revenue decline of 75.40%[2]. - The company reported total operating revenue of ¥663,079,213.63 for the current period, a decrease from ¥672,455,495.51 in the previous period, reflecting a decline of approximately 1.1%[17]. - Net profit for Q3 2024 was 15,265,671.36 CNY, down from 23,045,825.19 CNY in Q3 2023, representing a decrease of about 33.8%[19]. - The company's operating profit for Q3 2024 was 22,962,461.01 CNY, compared to 24,781,973.01 CNY in the same period last year, indicating a decline of approximately 7.3%[18]. - The total comprehensive income for Q3 2024 was 15,265,671.36 CNY, compared to 23,045,825.19 CNY in Q3 2023, reflecting a decrease of approximately 33.8%[19]. - The net profit attributable to shareholders of the parent company was 5,737,869.99 CNY in Q3 2024, down from 21,088,613.30 CNY in Q3 2023, a decline of about 72.8%[19]. Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date was -¥74,279,182.67, a decrease of 174.11% compared to the previous year[2]. - Cash flow from operating activities for Q3 2024 was 676,413,520.36 CNY, an increase from 598,365,400.52 CNY in Q3 2023, reflecting a growth of about 13.0%[19]. - The net cash flow from operating activities was -74,279,182.67, compared to -27,098,105.60 in the previous year, indicating a decline in operational cash flow[20]. - Total cash inflow from financing activities was 519,177,476.86, up from 383,534,918.63 in the same period last year, reflecting increased financing efforts[20]. - The net cash flow from investing activities was -105,062,585.00, slightly improved from -111,210,153.63 year-over-year[20]. - The company's cash and cash equivalents decreased by 31.11% to ¥145,476,608.46 due to increased investment in the Shandong Lingkai project[5]. - The company's cash and cash equivalents decreased to ¥145,476,608.46 from ¥211,179,872.15, representing a decline of approximately 30.9%[14]. - The total cash and cash equivalents at the end of the period were 81,395,864.50, down from 82,725,147.76 in the previous year[21]. - Cash outflow for operating activities totaled 781,201,639.32, compared to 653,835,226.10 in the previous year, showing increased operational expenses[20]. - Cash paid for purchasing goods and services was 346,475,462.26, up from 295,552,857.48 year-over-year, indicating higher procurement costs[20]. Assets and Liabilities - Total assets at the end of Q3 2024 were ¥2,144,371,675.82, reflecting a 0.51% increase from the end of the previous year[2]. - The company’s total liabilities decreased by 35.63% to ¥77,558,420.85, mainly due to the repurchase and cancellation of restricted stock[5]. - The company’s total liabilities stood at ¥1,049,353,506.86, down from ¥1,057,086,387.08, showing a decrease of approximately 0.3%[16]. - The company’s equity attributable to shareholders was ¥1,042,292,555.36, an increase from ¥1,033,194,655.74, reflecting a growth of about 0.1%[16]. - The company’s non-current assets totaled ¥1,298,737,001.31, up from ¥1,193,141,600.15, indicating an increase of about 8.8%[15]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 39,725[8]. - Sichuan Huasheng Group Co., Ltd. holds 17.87% of the shares, amounting to 111,431,281 shares, with 89,033,593 shares pledged[8]. - Chengdu Yuanhong Biotechnology Co., Ltd. indirectly holds 85.99% of Sichuan Huasheng Group Co., Ltd., the controlling shareholder[9]. - The company completed a share repurchase and cancellation of 442.32 million restricted stocks, reducing the total share capital from 628,142,564 shares to 623,719,364 shares[12]. - Chengdu Yuanhong plans to increase its stake in the company by investing between RMB 30 million and RMB 60 million, with a maximum purchase price of RMB 5 per share[11]. Expenses - The company's sales expenses increased by 60.15% to ¥203,048,791.93, primarily due to the acquisition of Tibet Kangyu[6]. - Research and development expenses decreased to 10,577,570.60 CNY in Q3 2024 from 12,695,497.98 CNY in Q3 2023, a reduction of approximately 16.7%[18]. - The company reported a significant increase in tax expenses, which rose to 9,298,934.08 CNY in Q3 2024 from 6,428,836.07 CNY in Q3 2023, an increase of about 44.0%[18].